COURT-RULING filed Sep 10, 2026 at 20:00 ET
PTC Therapeutics' trade secret lawsuit against AcureX Biosciences survived a motion to dismiss in part, with the court allowing PTC's core claim regarding the Proprietary Structural Motif to proceed while dismissing claims related to the assay cascade, know-how, and compound count. This is a partial win for PTC, preserving the most critical trade secret allegation and the breach of contract claim, but the case remains in early stages with no damages awarded or imminent resolution. The ruling removes the immediate risk of case dismissal but does not create a near-term catalyst for the stock given the long discovery and trial timeline ahead.